Copyright
©The Author(s) 2015.
World J Transl Med. Apr 12, 2015; 4(1): 25-37
Published online Apr 12, 2015. doi: 10.5528/wjtm.v4.i1.25
Published online Apr 12, 2015. doi: 10.5528/wjtm.v4.i1.25
Prognosis of primary GIST | ||
Risk | Size (cm) | Mitotic count (per 50 HPF) |
Very low risk | < 2 | < 5 |
Low risk | 2-5 | < 5 |
Intermediate risk | < 5 | 6-10 |
5-10 | < 5 | |
High risk | > 5 | > 5 |
> 10 | > Any mitotic rate | |
Any tumor | > 10 |
Agent | Molecular target | Phase |
Kinase inhibitors | ||
Nilotinib | KIT, PDGFRs, BCR-ABL | I |
Sorafenib | Raf, KIT, PDGFRB, VEGFR, FLT3, RET | 71% |
Dasatinib | Src, ABL, KIT, PDGFRs | Phase II ongoing in advanced sarcomas and accepting patients |
Cediranib (AZD2171) | VEGFR, KIT, PDGFRs | Phase II ongoing |
OSI-930 | VEGFR, KIT | Phase II ongoing, not recruiting |
Linsitinib (OSI-906 ) | IGF1R | Phase III |
Vatalanib (PTK787) | VEGFR, KIT, PDGFRs | 67% |
Motesanib (AMG706) | VEGFR, KIT, PDGFRs, RET | 24%-27% |
XL820 | KIT, PDGFRB, VEGFR | Phase II ongoing, not recruiting |
mTOR and AKT inhibitors | ||
Perifosine | AKT | Phase II ongoing in combination with imatinib |
Everolimus | mTOR | 26% |
Temsirolimus | mTOR | Phase II ongoing, closed recruitment |
Hsp90 inhibitors | ||
17-AAG | Hsp90 | Phase II/III |
Ganetespib (STA-9090) | Hsp90 | Phase II |
AUY922 | Hsp90 | Phase II |
AT13387 | Hsp90 | Phase II ongoing in combination with imatinib |
IPI-504 | Hsp90 | 78%, phase III ended due to safety concerns |
Others | ||
Flavopiridol | Transcription inhibitor | Phase I ongoing in combination with doxorubicin |
Clinical benefit is defined as complete or partial response or stable disease |
- Citation: Zhu JQ, Ou WB. Therapeutic targets in gastrointestinal stromal tumors. World J Transl Med 2015; 4(1): 25-37
- URL: https://www.wjgnet.com/2220-6132/full/v4/i1/25.htm
- DOI: https://dx.doi.org/10.5528/wjtm.v4.i1.25